Capítulo II: Aparición en España de un aislamiento clínico de

We found similar uptake of statins among HIV infected women when indicated, as compared to HIV uninfected patients, in the Women’s Interagency HIV Study. The 2013 ACC/AHA treatment guidelines, when applied to a population of HIV infected women, nearly tripled the number of women indicated for statin treatment, in comparison to the 2001 ATP III guidelines. Statins were moderately effective in lowering LDL cholesterol in both HIV infected and uninfected groups. In line with previous research, the reduction in LDL among HIV infected women was less than among HIV uninfected women.

REFERENCES

1. Sterne JAC, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366(9483):378–84.

2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med

1997;337(11):725–733.

3. Li T, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351(9117):1682–1686.

4. Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab 2011;25(3):429–42.

5. Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep 2012;9(3):206–17.

6. Executive Summary of the Third Report (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–2497.

7. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013;00:000–000.

8. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther 2012;17(6):1011–20.

9. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011;25(17):2113–22.

10. Stein JH, Komarow L, Cotter BR, et al. Lipoprotein Changes in HIV-Infected

Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s. J Clin Lipidol 2008;2(6):464–471.

11. Riddler S, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV- infected men on highly active antiretroviral therapy. HIV Med 2007;8:280–287.

12. Llibre JM, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS

2006;20(10):1407–14.

13. Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS

2011;25(2):185–95.

14. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17(8):1179–93.

15. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14(1):37–49.

16. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29(1):21–31. 17. Chêne G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in

lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002;34(5):649–57.

18. Armstrong C, Liu E, Okuma J, et al. Dyslipidemia in an HIV-Positive Antiretroviral Treatment-Naive Population in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2011;57(2):141–145.

19. Buchacz K, Weidle PJ, Moore D, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008;47(3):304–11.

20. Tadewos A, Addis Z, Ambachew H, et al. Prevalence of dyslipidemia among HIV- infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther 2012;9(1):31. 21. Pefura Yone EW, Kengne AP, Ashuntantang G, et al. Dyslipidaemia in HIV-1-infected

patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study. BMJ Open 2012;0:e001317.

22. Menezes CN, Maskew M, Sanne I, et al. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis 2011;11(1):244.

23. Nachega JB, Hsu AJ, Uthman O a, et al. Antiretroviral therapy adherence and drug- drug interactions in the aging HIV population. AIDS 2012;26 Suppl 1(December 2011):S39–53.

24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at

http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf. 25. Wohl DA. Deconstructing most recent antiretroviral recommendations. Curr

HIV/AIDS Rep 2010;7(2):77–84.

26. D’Agostino RB, Ansell BJ, Mora S, et al. Clinical Decisions. The Guidelines Battle on Starting Statins. N Engl J Med 2014;370(17):1652–1658.

27. Pencina MJ, Navar-Boggan AM, D’Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370(15):1422–31. 28. Fang MC, Coca Perraillon M, Ghosh K, et al. Trends in stroke rates, risk, and

outcomes in the United States, 1988 to 2008. Am J Med 2014;127(7):608–615. 29. Myerson M, Poltavskiy E, Armstrong E, et al. Prevalence, Treatment and Control of

Dyslipidemia and Hypertension in 4278 HIV Outpatients. J Acquir Immune Defic Syndr 2014;66(4):370–377.

30. Silverberg MJ, Leyden W, Hurley L, et al. Response to Newly Prescribed Lipid- Lowering Therapy in Patients With and Without HIV Infection. Ann Intern Med 2009;150(5):301–314.

31. Singh S, Willig JH, Mugavero MJ, et al. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. Clin Infect Dis 2011;52(3):387–395. 32. Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus pravastatin in

dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010;24(1):77–83.

33. Bonnet F, Balestre E, Thiébaut R, et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med 2004;5(3):133–9.

34. Eckard A, Jiang Y, Debanne S, et al. Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral

Therapy. J Infect Dis 2014;209(8):1156–1164.

35. Wohl D, Mccomsey G, Tebas P, et al. Current Concepts in the Diagnosis and

Management of Metabolic Complications of HIV Infection and Its Therapy. Clin Infect Dis 2006; 43:645–653.

36. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978–82.

37. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City. Ann Intern Med 2006; 145:397–406.

38. The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387–1396.

39. The Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537–1548.

40. CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741–749.

41. Loutfy MR, Sherr L, Sonnenberg-schwan U, Walmsley SL, Johnson M. Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc 2013; 16:1–14.

42. Adimora AA, Schoenbach VJ, Floris-Moore MA. Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med 2009; 37:468–71. 43. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life

expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49:1570–8.

44. Aral SO, Adimora AA, Fenton KA. Understanding and responding to disparities in HIV and other sexually transmitted infections in African Americans. Lancet 2008; 372:337–40.

45. Squires K. Gender Differences in the Diagnosis and Treatment of HIV. Gend Med 2007; 4:294–307.

46. Hirschhorn LR, McInnes K, Landon BE, et al. Gender differences in quality of HIV care in Ryan White CARE Act-funded clinics. Womens Health Issues 2006; 16:104– 12.

47. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38:96–103.

48. Mangione CM, Reynolds E. Disparities in health and health care. J Gen Intern Med 2001; 16:276–280.

49. Zierler S, Krieger N. Reframing Women’s Risk: Social Inequalities and HIV Infection. Annu Rev Public Health 1997; 18:401–436.

50. Nguyen JT, Berger AK, Duval S, Luepker RV. Gender Disparity in Cardiac Procedures and Medication Use for Acute Myocardial Infarction. Am Heart J 2008; 155:862–868. 51. Carlisle DM, Leake BD, Shapiro MF. Racial and Ethnic Disparities in the Use of

Cardiovascular Procedures: Associations with Type of Health Insurance. Am J Public Health 1997; 87:263–267.

52. Ayanian J, Udvarhelyi I, Gatsonis C, Pashos C, Epstein A. Racial differences in the use of revascularization procedures after coronary angiography. JAMA 1993; 269:2642– 6.

53. Whittle J, Conigliaro J, Good C, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med 1993; 329:621–627.

54. Krumholz HM, Douglas PS, Lauer MS. Selection of Patients for Coronary

Angiography and Coronary Revascularization Early after Myocardial Infarction: Is There Evidence for a Gender Bias? Ann Intern Med 1992; 116:785–790.

55. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991; 325:221–225. 56. Zweifler RM, McClure LA, Howard VJ, et al. Racial and geographic differences in

prevalence, awareness, treatment and control of dyslipidemia: the reasons for geographic and racial differences in stroke (REGARDS) study. Neuroepidemiology 2011; 37:39–44.

57. Goff DC, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006; 113:647–56.

58. Bacon MC, Wyl V Von, Alden C, et al. The Women’s Interagency HIV Study: an

Observational Cohort Brings Clinical Sciences to the Bench. Clin Diagn Lab Immunol 2005; 12:1013–1019.

59. van der Laan MJ, Rubin D. Targeted Maximum Likelihood Learning. Int J Biostat 2006; 2.

60. van der Laan MJ, Rose S. Targeted Learning: Causal Inference for Observational and Experimental Data. Springer, 2011.

61. Rose S. Mortality risk score prediction in an elderly population using machine learning. Am J Epidemiol 2013; 177:443–52.

62. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656–64.

63. Porter KE, Gruber S, van der Laan MJ, Sekhon JS. The relative performance of targeted maximum likelihood estimators. Int J Biostat 2011; 7.

64. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53(282).

65. Efron B. Nonparametric estimates of standard error: The jackknife, the bootstrap and other methods. Biometrika 1981; 68:589-599.

66. Stone CJ, Koo CY. Additive splines in statistics. Proc Stat Comp Sect Am Statist Assoc 1985; 45-58.

67. Efron B. The Efficiency of Cox’s Likelihood Function for Censored Data. J Am Stat Assoc 1977; 72:557-565.

68. VanderWeele TJ. Concerning the consistency assumption in causal inference. Epidemiology 2009; 20:880–3.

69. Hudgens MG, Halloran ME. Toward Causal Inference with Interference. J Am Stat Assoc 2008; 103:832–842.

70. Robins JM, Hernán MA, Brumback B. Marginal Structural Models and Causal Inference in Epidemiology. Epidemiology 2000; 11:550–560.

71. Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013; 61:511–23.

72. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011; 32:945–51.

73. The Writing Committee of the D:A:D: Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18:1811–1817.

74. O’Halloran JA, Satchell CS, Mallon PW. Dyslipidemia, atherosclerosis and

cardiovascular disease: an increasingly important triad in an aging population living with HIV. Future Virol 2013; 8:1021–1034.

75. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569–77.

76. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials. Am J Med 1998, 104:2S-5S.

77. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000; 20:1066–71.

78. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352:1031–1032.

79. Park TE, Sharma R, Yusuff J, et al. Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human

immunodeficiency virus. 53rd ICAAC. September 10-13, 2013. Denver. Abstract H- 1257.

80. Mascolini, M. Low aspirin or statin use for primary MI/stroke prevention at HIV clinic. 53rd ICAAC. September 10-13, 2013. Denver.

81. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003; 14:680–6.

82. Cole SR, Hudgens MG, Brookhart MA, Westreich D. Risk. Am J Epidemiol 2015; 181:246–250.

83. Howe CJ, Cole SR, Westreich DJ, Greenland S, Napravnik S, Eron JJ. Splines for trend analysis and continuous confounder control. Epidemiology 2011; 22:874–875. 84. Harrell, FE, Jr. [October 13, 2015] DASPLINE Macro.

http://biostat.mc.vanderbilt.edu/twiki/pub/Main/SasMacros/survrisk.txt 85. Zanni MV, Fitch KV, Feldpausch M, et al. 2013 American College of

Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS 2014; 28:2061–2070.

86. Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-infected Subjects on

Antiretroviral Therapy: the SATURN-HIV Trial. Clin Infect Dis 2014; 59:1148–1156. 87. Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of Age With

Polypharmacy and Risk of Drug Interactions With Antiretroviral Medications in HIV- Positive Patients. Ann Pharmacother 2013; 47:1429–1439.

88. Holtzman C, Armon C, Tedaldi E, et al. Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population. J Gen Intern Med 2013; 28:1302–1310.

89. Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The Next Therapeutic Challenge in HIV: Polypharmacy. Drugs Aging 2013; 30:613–628. 90. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with

protease inhibitors. Lancet 1998; 351:1328.

91. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women’s Interagency HIV Study. Epidemiology 1998; 9:117–125.

92. Ray WA. Evaluating Medication Effects Outside of Clinical Trials: New-User Designs. Am J Epidemiol 2003; 158:915–920.

93. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163:1149–56.

94. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? Epidemiology 2009; 20:3–5.

95. Westreich D, Cole SR. Invited commentary: positivity in practice. Am J Epidemiol 2010; 171:674–7; discussion 678–81.

96. Bang H, Robins JM. Doubly robust estimation in missing data and causal inference models. Biometrics 2005; 61:962–73.

97. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is baseline

adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol 2005; 162:267–78.

98. Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994; 78:225–245.

99. Levy RI, Troendle AJ, Fattu MA. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMGCoA reductase inhibitor fluvastatin. Circulation 1993;87(Suppl):11 145–11 153.

100. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994;154:1586-95.

101. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582–7.

102. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1: 495–505.

103. Knopp R. Drug treatment of lipid disorders. New Engl J Med 1999; 341: 498–511. 104. Ferdinand KC, Clark LT, Watson KE, et al. Comparison of efficacy and safety of

Rosuvastatin versus Atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006; 97:229–235.

105. Hernán MA, Hernández-Díaz S, Robins JM. A Structural Approach to Selection Bias. Epidemiology 2004; 15:615–625.